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Monoclonal antibodies (Mab) were raised against CRM197, a non-toxic mutant of diphtheria toxin (DT). 
The ability of four Mabs to bind DT and the six functional mutants CRM197, CRM176, CRM228, 
CRMlOOl, CRM45 and CRM30 was assessed by immunoblotting and by a radioimmunoassay in which 
the protein antigen in solution competes with labeled CRM197 for the Mab binding site. The results show 
that the peptides recognized by Mabl 1.3, Mab53 and Mab23 are accessible in the mutant molecules in solu- 
tion but not when they are part of the native DT structure, which could therefore be described for this pur- 
pose as ‘closed’ in contrast with an ‘open’ conformation of CRM 197, CRM 176 and CRM228. In particular, 
the behaviour of Mab53 indicates that the single amino acid substitutions in the A fragments of CRM197 
and CRM176 also affect he conformation f their B fragments. 
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1. INTRODUCTION 
Diphtheria toxin (DT) is a 58 350 Da protein 
[1,2] which is synthesized by C. diphtheriae when 
lysogenized by a corynephage (tax+) and is re- 
leased extra-cellularly as a single polypeptide [3,4]. 
DT can be easily split by limited proteolytic diges- 
tion into two functionally independent fragments, 
A and B (fig. 1). The amino-terminal fragment A is 
an enzyme responsible for the potent cytotoxic ac- 
tion of DT since it catalyses ADP-ribosylation, 
and consequent inactivation, of elongation fac- 
tor-2, present in all eukaryotic ribosomes. How- 
ever, fragment A is toxic only in the presence of 
the carboxy-terminal fragment B, which is re- 
quired for the binding to specific receptors on the 
surface of sensitive eukaryotic cells, consequent 
uptake into endosomes, and translocation of frag- 
ment A into the cytosol [5]. 
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Although DT has been crystallized in a form 
suitable for x-ray diffraction studies [6,7], direct 
information on the tertiary folding of this protein 
has not been forthcoming so far, and models aim- 
ing to understand structure-function relationships 
in DT rely mainly on analysis of functional mu- 
tants. The most important group of such mutants 
was produced by nitrosoguanidine mutagenesis of 
the tox gene of corynephage-fi (tax+) and infec- 
tion of a virus-free C. diphtheriae strain. Several 
proteins were obtained which were either non-toxic 
or had a markedly reduced toxicity and were 
serologically related to DT [g-lo]. Several of these, 
generally called cross-reacting materials (CRMs), 
are well characterized [4] and, recently, the altera- 
tion in their primary structure was analyzed by se- 
quencing the corresponding genes ([ 1 l- 141 and our 
unpublished data); see fig.1. In this work we used 
monoclonal antibodies raised against CRM197, as 
structural probes for the tertiary structure by 
testing their interaction with DT and six functional 
mutants. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 271 
Volume 218, number 2 FEBS LETTERS June 1987 
2. MATERIALS AND METHODS 
2.1. Cell culture media 
10% or 20% DMEM: Dulbecco’s modified 
Eagle’s medium plus 10% or 20% fetal calf serum 
(Flow Laboratories). All sera were inactivated 
(6O”C, 30 min) before use. 
HAT medium: 20% DMEM supplemented with 
hypoxantine (13.6 pg/ml), thymidine (3.87 pg/ml) 
and aminopterin (0.176 pg/ml). 
HT medium: HAT medium without aminop- 
terin. 
2.2. Dipheria toxin and related mutants 
Diphtheria toxin and related mutants (CRMs) 
were produced and purified as described [ 15-171. 
The concentration of DT and CRMs were deter- 
mined by the method of Bradford [18], and by 
rocket immunoelectrophoresis, as described [19]. 
2.3. Production of monoclonal antibodies anti- 
CRM 197 
4-week-old Balb/c mice were immunized in- 
traperitoneally with a total of 130 pg of purified 
CRM197 (4 injections at one week intervals). 
Hybridoma cell lines were prepared according to 
Galfre and Milstein [20]. 
2.4. Purification of antibodies 
All the Mabs chosen belonged to the IgGl 
subclass, and were purified by affinity chromato- 
graphy on Protein A Sepharose CL4B (Phar- 
macia) [21]. 
2.5. Immunoblot analysis 
Electrophoresis was performed using partially 
nicked and reduced DT or CRM samples on SDS- 
polyacrylamide gels according to Laemmli [22]. 
Western blot analysis of purified monoclonal an- 
tibodies was performed as described by Towbin et 
al. [23] and Robb et al. [24]. 
2.6. Radioimmunoassays 
The affinity constants of the Mabs were deter- 
mined by non-linear regression analysis after com- 
petitive solid-phase radioimmunoassay [25] with 
CRM197 labeled with lz51 using NaI and lac- 
toperoxidase as described by Marchalonis [26]; the 
specific activity was 60 ,&i/pg. The test was per- 
formed by adsorbing the antibody on the wells of 
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microtiter plates and measuring the amount of 
‘251-labeled CRM197 which was bound to the solid 
phase in the presence of increasing amounts of the 
antigen, i.e. DT or CRM, under examination. The 
epitope specificity of the Mabs was determined by 
a competitive solid-phase antibody binding assay, 
according to Ivanyi [27] and Stahli et al. [28]. 
2.7. Cytotoxicity assays 
Cytotoxicity neutralization tests were performed 
as described [29,30]. The antibody solutions were 
adjusted to lOOpg/ml and lo-fold serial dilutions 
were made in 10% DMEM. These samples were 
pre-incubated with DT at different concentrations, 
for 1 h at 37°C and transferred onto the CHO cell 
cultures. After 3 days, live cells were stained with 
gentian violet and the amount of dye estimated 
with the help of a Titertek plate reader (Flow 
Laboratories) at 560 nm. 
3. RESULTS 
14 monoclonal antibodies against CRM197 were 
obtained and divided into 4 groups on the basis of 
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Fig. 1. Schematic representation of diphtheria toxin and 
related functional mutants (CRMs). Fragment A (21 
kDa) and fragment B (37 kDa) and the amino acid 
residues involved in the mutations are indicated. The 
data are deduced from [l and 21 for DT, [lo] for 
CRM228, [l l] for CRM197, CRM45 and CRM30, [12] 
for CRM176, and our unpublished DNA sequencing 
data for CRM176 and CRMlOOl. 
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Fig.2. Antibody binding to diphtheria toxin on Western 
blots. A purified DT preparation in which -50% 
molecules were split into fragments A and B, was used 
to obtain a blot which was cut into stripes and probed 
with different antibodies. Lane 1: blot of DT stained 
with amido-black; the major bands are from top to bot- 
tom: intact DT, fragment B, fragment A. Lanes 2 to 6: 
binding to different antibodies; Mabl 1.3, Mabl, 
Mab53, Mab23 and a control with a monoclonal IgGl to 
the human chorionic somatotropin, respectively. 
a competitive solid-phase binding assay [23,25] 
where the ability of two antibodies to compete for 
the same epitope was assessed. One representative 
antibody for each group was selected (Mabl, 
Mab11.3, Mab53, Mab23) and used for further 
studies. Immunoblot analysis on electrophoretical- 
ly separated fragments A and B (fig.2) showed that 
Mab11.3 recognizes an epitope on fragment A, 
while Mabs 1, 53 and 23 recognize different 
epitopes on fragment B. A better mapping within 
fragment B was then obtained by using the same 
technique with all the CRMs (not shown) and scor- 
ing the ability of each antibody to detect the 
mutated B fragments of CRM45, CRM30, 
CRM228 and CRMlOOl. In particular, the two C- 
terminally truncated CRMs 30 and 45 allowed a 
subdivision of fragment B into 3 portions (see 
fig.1): a first N-terminal portion (region Bl) up to 
the COOH-end of CRM30; a second portion 
(region B2) comprising essentially the central 
hydrophobic region between the COOH-ends of 
CRM30 and CRM45; a third portion (region B3) 
comprising the last 149 amino acid residues and in- 
cluding the putative receptor binding domain [3,4]. 
Mabl and Mab23, which recognized the B 
fragments of DT and all the CRMs tested, in- 
cluding CRM30, are therefore directed towards 
peptides of region Bl . Mab53 recognized fragment 
B of DT, CRM197, CRM176 (all with the same 
primary structure) and also that one of CRM228 
(with 3 amino acid substitutions); however, Mab 
53 could not bind either CRM30 or CRM45 and 
therefore the target of this antibody must be within 
the region B3 (residues 386-535). Furthermore 
Mab53 did not react with CRMlOOl which has a 
mutation in this region (Cys-471 to Tyr): it is 
therefore likely that Mab53 recognizes a peptide 
including, or very close to, Cys-471. These results 
are summarized in table 1. 
The binding properties of the Mabs were also ex- 
amined by a competition radioimmunoassay where 
the antibody is bound to the solid phase and the 
antigen under test, in solution, competes with lz51- 
labeled CRM197. The same preparation of labeled 
CRM197 was used throughout all tests. Values 
below 1 x 10’ M-r were considered as background 
or non-specific binding, since they are sometimes 
obtainable even with heterologous antibodies. The 
results, are shown in table 1. The Mabs were also 
tested for their ability to neutralize the cytotoxic 
action of DT on CHO cells in culture: only Mabl 
showed any toxin neutralizing activity. 
4. DISCUSSION 
The properties of four monoclonal antibodies 
raised against the diphtheria toxoid CRM197 were 
studied. Immunoblot analysis using a panel of 
molecularly characterized mutants (see fig. 1) 
allowed a rough mapping along the amino acid se- 
quence. 4 regions were considered: fragment A 
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Table 1 
Summary of interactions of antibodies with DT and CRMs 
Mab Epitope CHO Interactions with DT and CRMs 
regiona protection 
DT 197 176 228 1001 30 45 
11.3 A 
53 B3 
23 Bl 
1 Bl 
no Kad: 0 2.6 0.5 0.3 0 <O.l 0 
blot: += + + + + + + 
no Ka: 0 8.7 14.6 1.1 0.1 0 0 
blot: + + + + - - - 
no Ka: 0 0.4 6.5 6.6 4.1 5.4 34.7 
blot: + + + + + + + 
yesb KG 192 120 105 540 32.5 1.5 463 
blot: + + + + + + + 
aA, fragment A; Bl,B2,B3, regions of fragment B as described in the text 
bMolar ratio Mab : toxin = 92 
‘+/- refers to the antibody’s ability to detect the various proteins on immunoblots 
d Ka, affinity constants; figures are Kax 10m6 M-‘, values <O.l vary from lo-’ to 10m4 
plus three regions of fragment B separated by the 
COOH-ends of CRM30 and CRM45 and called 
here Bl, B2 and B3. Mabll.3 is directed towards 
fragment A; Mabl and Mab23 are directed, to- 
wards different epitopes in region Bl; Mab53 is 
directed towards the C-terminal of region B3 and 
probably binds to a peptide including, or very close 
to, cys-47 1. 
We then measured the affinity constants of the 
Mabs for their epitopes when these are in their 
native tertiary structure (table 1). 
Mabl (which gives a fairly strong interaction 
with all the molecules tested and has the value of 
a positive control) is the only antibody capable of 
neutralizing DT’s toxicity for CHO cells. In this 
respect it is interesting to note that cytotoxicity 
neutralization does not necessarily correlate (in an 
assay similar to the one we used) with a high affini- 
ty but with inhibition of toxin binding to its recep- 
tor [31]. The location of the site recognized by 
Mabl within the region Bl supports the suggestion 
that an N-terminal portion of fragment B is also 
involved in this process besides the primary re- 
ceptor-binding domain located within region B3. 
Mab 11.3 discriminates between the A fragments 
of CRM197, CRM176 and CRM228 (all mutated 
and fully or partially inactivated) and the same 
fragment in its wild-type configuration (as in DT, 
CRM45, CRM30 and CRMlOOl). 
Mab53 has no affinity for CRMlOOl, CRM30 
and CRM45 in agreement with the immunoblot 
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analysis. However, its behaviour with the wild- 
type B’fragments present in DT, CRM197 and 176 
is unexpected since it fails to bind DT while reac- 
ting well with both CRM197 and CRM176. 
Mab23 binds all the CRMs of the panel but, as 
Mab53, does not bind DT. The variation in affini- 
ty values of Mab23 for the CRMs could be related 
to different structures of their B fragments. The 
highest affinity was obtained for CRM45, possibly 
because the epitope involved is better exposed in 
this C-terminally truncated molecule. 
The results reported here support the view that 
DT’s structure can assume ‘open’ and ‘closed’ con- 
figurations. Mabl would bind to a major surface 
determinant exposed in both configurations 
(higher affinities, toxicity neutralization), whereas 
Mabs 53, 23 and 11.3 would bind to epitopes ac- 
cessible only in the ‘open’ structures adopted by 
the functional mutants here examined. Zucker and 
Murphy [3 l] reported in a recent study the analysis 
of 43 monoclonal antibodies raised using a detox- 
ified DT preparation and found that none of them 
was directed against the amino-terminal Bl region 
of fragment B; also, when they tested the reactivity 
of the peptide between Cys-461 and Cys-471 they 
found that none of their monoclonal antibodies or 
a polyclonal antitoxin serum reacted with this pep- 
tide. Furthermore, all the 16 monoclonal an- 
tibodies directed against fragment A mapped 
within a region comprising only 20% of the frag- 
ment. All this is consistent with the view that Mabs 
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11.3, 23 and 53 interact in CRM197 and CRM176 
with regions which are not exposed in native DT in 
solution at a neutral pH. 
The data obtained with Mab53 indicate that the 
structure of fragment B in CRM197 (which has a 
primary structure identical to that of DT and can 
complement in vitro a native fragment A. to re- 
constitute a fully toxic molecule, [9]) differs from 
the same polypeptide in the wild-type configura- 
tion as a consequence of a single amino acid 
substitution in fragment A, which introduces a 
charged residue in the place of a glycine. These 
findings point to a tight interaction between the 
two fragments, and are in agreement with a 
number of previous observations: namely, (i) the 
CD spectra of DT and CRM197 are different 
[32,33]; (ii) CRM197 is more susceptible than DT 
to the action of proteases ([7] and unpublished 
observations); (iii) the interaction of fragment B of 
CRM197 with lipid membranes is stronger than 
that of the same fragment in DT [34]. This last 
property described in the recent work of Papini et 
al. [34] could explain why the affinity of CRM197 
for the cell receptors is apparently higher than that 
of DT [32]. 
Similar considerations applied to the structure 
of CRM176 would explain why its toxicity is 
200-times lower than that of DT [23], although the 
enzymatic activity in vitro of its fragment A is only 
lo-times lower than that of wild-type fragment A 
[S-lo] and its fragment B has the same primary 
structure as DT. It seems likely, that such a tight in- 
teraction between A and B fragments as in 
CRM176 and CRM197 can exist in the native toxin 
as well. 
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